原发性中枢神经系统淋巴瘤的挑战
The Challenge of Primary Central Nervous System Lymphoma.
作者信息
Carnevale Julia, Rubenstein James L
机构信息
Division of Hematology/Oncology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.
Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, M1282 Box 1270, San Francisco, CA 94143, USA.
出版信息
Hematol Oncol Clin North Am. 2016 Dec;30(6):1293-1316. doi: 10.1016/j.hoc.2016.07.013.
Abstract
Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor.
摘要
原发性中枢神经系统（CNS）淋巴瘤是侵袭性非霍奇金淋巴瘤中一种具有挑战性的亚型。新出现的临床数据表明，采用剂量密集型可穿透中枢神经系统的化疗并避免全脑放疗可实现最佳治疗效果。基于抗CD20抗体的免疫疗法作为基于大剂量甲氨蝶呤的诱导方案的一部分，可能有助于改善治疗效果。对疾病发病机制的分子和细胞基础的深入了解正在为开发分子工具以促进诊断提供基础，同时也为在这种具有挑战性的脑肿瘤的治疗手段发展中整合靶向治疗提供了路线图。
相似文献
1
The Challenge of Primary Central Nervous System Lymphoma.
Hematol Oncol Clin North Am. 2016 Dec;30(6):1293-1316. doi: 10.1016/j.hoc.2016.07.013.
2
Current management of primary central nervous system lymphoma.
Chin Clin Oncol. 2017 Aug;6(4):38. doi: 10.21037/cco.2017.06.24.
3
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703.
4
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):444-7. doi: 10.7534/j.issn.1009-2137.2016.02.025.
5
Primary central nervous system lymphoma: essential points in diagnosis and management.
Med Oncol. 2017 Apr;34(4):61. doi: 10.1007/s12032-017-0920-7. Epub 2017 Mar 17.
6
[Primary central nervous lymphoma: what is the role for radiotherapy?].
Cancer Radiother. 2014 Nov;18(7):685-92. doi: 10.1016/j.canrad.2014.06.025. Epub 2014 Oct 18.
7
Diagnosis and management of primary central nervous system lymphoma.
Cancer. 2017 Nov 15;123(22):4314-4324. doi: 10.1002/cncr.30965. Epub 2017 Sep 26.
8
Proton Beam Therapy for Adolescent Primary Central Nervous System Lymphoma With Residual Tumor After Intensive Chemotherapy: A Case Report.
Pract Radiat Oncol. 2019 Sep-Oct;9(5):333-337. doi: 10.1016/j.prro.2019.05.005. Epub 2019 May 22.
9
Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Am J Hematol. 2015 Dec;90(12):1149-54. doi: 10.1002/ajh.24204. Epub 2015 Nov 17.
10
[Primary CNS lymphoma. Progress in the diagnostics and therapy].
Nervenarzt. 2015 Jun;86(6):710-2, 714-5. doi: 10.1007/s00115-014-4227-z.
引用本文的文献
1
Bilateral Facial Nerve Palsy Revealing Diffuse Large B-Cell Lymphoma With Leptomeningeal Involvement.
Cureus. 2025 Jun 26;17(6):e86828. doi: 10.7759/cureus.86828. eCollection 2025 Jun.
2
Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis.
J Control Release. 2025 May 10;381:113611. doi: 10.1016/j.jconrel.2025.113611. Epub 2025 Mar 13.
3
A disease warranting attention from neurosurgeons: primary central nervous system post-transplant lymphoproliferative disorder.
Front Neurol. 2024 May 15;15:1392691. doi: 10.3389/fneur.2024.1392691. eCollection 2024.
4
Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India.
Indian J Hematol Blood Transfus. 2023 Jan;39(1):57-70. doi: 10.1007/s12288-022-01557-7. Epub 2022 Sep 6.
5
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
BMC Cancer. 2022 Feb 20;22(1):190. doi: 10.1186/s12885-022-09275-z.
6
Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.
Adv Drug Deliv Rev. 2022 Feb;181:114033. doi: 10.1016/j.addr.2021.114033. Epub 2021 Nov 20.
7
MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.
Neurooncol Adv. 2021 Jul 7;3(1):vdab090. doi: 10.1093/noajnl/vdab090. eCollection 2021 Jan-Dec.
8
Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma.
Children (Basel). 2021 Jun 2;8(6):469. doi: 10.3390/children8060469.
9
Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.
Cancers (Basel). 2021 May 28;13(11):2665. doi: 10.3390/cancers13112665.
10
Primary Central Nervous System Lymphoma Mimicking Longitudinally Extensive Transverse Myelitis.
Neurohospitalist. 2021 Apr;11(2):170-174. doi: 10.1177/1941874420967560. Epub 2020 Oct 16.
本文引用的文献
1
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.
2
Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
AJR Am J Roentgenol. 2015 Nov;205(5):1075-85. doi: 10.2214/AJR.14.13970.
3
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.
Neuro Oncol. 2016 Apr;18(4):575-81. doi: 10.1093/neuonc/nov253. Epub 2015 Oct 20.
4
The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.
AJNR Am J Neuroradiol. 2016 Jan;37(1):74-9. doi: 10.3174/ajnr.A4450. Epub 2015 Sep 17.
5
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Blood. 2015 Aug 6;126(6):779-89. doi: 10.1182/blood-2015-02-628669. Epub 2015 May 22.
6
High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.
Blood. 2015 Jul 2;126(1):76-9. doi: 10.1182/blood-2015-01-620518. Epub 2015 Apr 21.
7
New approaches in primary central nervous system lymphoma.
Chin Clin Oncol. 2015 Mar;4(1):11. doi: 10.3978/j.issn.2304-3865.2015.02.01.
8
Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Neuro Oncol. 2015 Jul;17(7):1016-21. doi: 10.1093/neuonc/nov046. Epub 2015 Mar 26.
9
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7.
10
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Leukemia. 2015 Mar;29(3):677-85. doi: 10.1038/leu.2014.264. Epub 2014 Sep 5.
Zotero 插件